Do we cause false positives? An experimental series on droplet or airborne SARS-CoV-2 contamination of sampling tubes during swab collection in a test center.


Journal

Antimicrobial resistance and infection control
ISSN: 2047-2994
Titre abrégé: Antimicrob Resist Infect Control
Pays: England
ID NLM: 101585411

Informations de publication

Date de publication:
09 03 2021
Historique:
received: 01 01 2021
accepted: 26 02 2021
entrez: 22 3 2021
pubmed: 23 3 2021
medline: 7 4 2021
Statut: epublish

Résumé

The rapid spread of the coronavirus disease 2019 pandemic urged immense testing capacities as one cornerstone of infection control. Many institutions opened outpatient SARS-CoV-2 test centers to allow large number of tests in comparatively short time frames. With increasing positive test rates, concerns for a possible airborne or droplet contamination of specimens leading to false-positive results were raised. In our experimental series performed in a dedicated SARS-CoV-2 test center, 40 open collection tubes placed for defined time periods in proximity to individuals were found to be SARS-CoV-2 negative. These findings argue against false-positive SARS-CoV-2 results due to droplet or airborne contamination.

Identifiants

pubmed: 33750477
doi: 10.1186/s13756-021-00920-z
pii: 10.1186/s13756-021-00920-z
pmc: PMC7941134
doi:

Substances chimiques

Particulate Matter 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

51

Références

JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Lancet Respir Med. 2020 Jul;8(7):658-659
pubmed: 32473123
JAMA. 2020 Apr 28;323(16):1610-1612
pubmed: 32129805
N Engl J Med. 2020 Apr 16;382(16):1564-1567
pubmed: 32182409

Auteurs

Thomas Scheier (T)

Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland. thomas.scheier@usz.ch.

Cyril Shah (C)

Institute of Medical Virology, University of Zurich, Zurich, Switzerland.

Michael Huber (M)

Institute of Medical Virology, University of Zurich, Zurich, Switzerland.

Hugo Sax (H)

Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.

Barbara Hasse (B)

Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.

Huldrych F Günthard (HF)

Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Institute of Medical Virology, University of Zurich, Zurich, Switzerland.

Alexandra Trkola (A)

Institute of Medical Virology, University of Zurich, Zurich, Switzerland.

Peter W Schreiber (PW)

Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH